BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jun 14, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

STA-9090: Updated Phase I data

Updated data from an ongoing, open-label, dose-escalation Phase I trial in 26 evaluable patients showed that twice-weekly STA-9090 produced 1 partial response in a melanoma patient and 10 cases of...

Read the full 126 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >